For how we live.
In 216 patients with chronic patellofemoral pain across 10 Korean hospitals, an 8-week digital therapeutic beat education and exercise instruction on pain — by 12.5 mm on a 100 mm scale.
Thirty-two interviews across Uruguay, Argentina, Chile and Mexico find implementation turned on governance, not software. A separate patent analysis shows where digital therapeutics are not being built.
In a study of 543,167 cycles, calendar-based apps misclassified a fertile day as safe in two-thirds of cycles. Apps that track a real biological signal do better, but plain calendar apps remain the most common kind.
A new structured dataset finally makes the approvals countable. Two trials published weeks apart show why counting them says little: 0.86 fewer migraine days in one, a 20-point symptom shift in the other.
Germany's DINKS trial is one of the largest randomised tests of a reimbursable digital therapeutic. The effect is big, the comparator is usual care alone, and the sponsor made the app.
Across 40 trials, self-guided apps moved panic severity modestly and barely touched fear-related cognitions. Clinician-guided versions moved both — which complicates the scalability pitch.
In 311 adults aged 55 to 95, remission rates were 40% and 51% in the two intervention arms at one year, against 16% for online patient education. Adding human support helped a little.